运动与甲胺在尼日利亚糖尿病前期患者中的影响:一项随机对照试验
M T Umar1, A A Sabir1, K B Sada2
1Department of Medicine, Usmanu Danfodiyo University Teaching Hospital, Sokoto. Email: musatambuwal@gmail.com; Phone Number: 2348063045900.
West African journal of medicine
|August 28, 2024
概括
适度运动和甲福明显著改善了尼日利亚糖尿病前期患者的葡萄糖耐受性,可相互比较,优于安慰剂. 这些干预措施还可以降低糖尿病风险.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 公共卫生 公共卫生
背景情况:
- 糖尿病前期是尼日利亚普遍存在的2型糖尿病的重要危险因素.
- 有效的干预措施可以逆转糖尿病前期相关的碳水化合物不耐受性.
- 尼日利亚之前没有研究过糖尿病前期的结果或干预措施.
研究的目的:
- 为了比较适度运动和甲胺对尼日利亚糖尿病前期患者葡萄糖耐受性的影响.
- 为了评估与安慰剂对抗的干预措施,用于糖尿病前期管理.
主要方法:
- 一个随机的安慰剂受控试验,涉及54名尼日利亚糖尿病前期患者.
- 参与者接受了甲胺,中度运动或安慰剂12周.
- 在干预前和后测量了血葡萄糖水平.
主要成果:
- 与安慰剂相比,适度运动和甲福明都显著降低了禁食血葡萄糖 (FPG) 和2小时后葡萄糖负载 (2HPGL) 水平.
- 运动组显示6.4%的FPG和20.5%的2HPGL减少 (p<0.05).
- 甲福明组显示13.3%的FPG和12.4%的2HPGL减少 (p<0.05),分别减少了50%和40%的糖尿病风险.
结论:
- 适度运动和甲胺是改善尼日利亚糖尿病前期患者葡萄糖耐受性的有效干预措施.
- 运动和甲福明在改善葡萄糖耐受性和降低糖尿病风险方面表现出相似的有效性.
- 需要进行长期跟踪,以评估这些干预措施的持续影响.
更多相关视频
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Carbohydrate Metabolism
10.9K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.9K
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178


